Otonomy

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Otonomy is an expert in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes, and from these, three product candidates have been advanced into development.

Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020 Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020

Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update

SAN DIEGO, July  13, 2020  (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closing of its previously announced underwritten public offering of 17,275,000 shares of its common stock, which includes the underwriters' full exercise of their option to purchase additional shares and pre-funded warrants to purchase up to 4,000,000 shares of its common stock, for total gross proceeds of approximately $69.1 million, before deducting the underwriting discounts and commissions and other offering expenses payable by Otonomy. All of the securities were sold by Otonomy.

Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Otonomy (OTIC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Otonomy (OTIC) Catches Eye: Stock Jumps 9.1%

SAN DIEGO, July  09, 2020  (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price to the public of $3.25 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 4,000,000 shares of its common stock at a purchase price of $3.249 per each pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $60.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by Otonomy. In addition, Otonomy has granted the underwriters a 30-day option to purchase up to an additional 2,775,000 shares of its common stock in connection with the public offering at the public offering price per share, less underwriting discounts and commissions.  All of the shares of common stock and pre-funded warrants are being sold by Otonomy. The offering is expected to close on or about July 13, 2020, subject to customary closing conditions. 

Otonomy Announces Pricing of $60.1 Million Public Offering

Otonomy (NASDAQ: OTIC) shares are trading higher on Tuesday. The company reported results from its Phase 1/2 clinical trial of OTO-313 in patients with Tinnitus demonstrated a higher proportion of responders than placebo.

Why Otonomy's Stock Is Trading Higher Today

SAN DIEGO, July  06, 2020  (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive top-line results from the Phase 1/2 clinical trial of OTO-313 in patients with persistent tinnitus of at least moderate severity. The exploratory efficacy cohort of the trial included 31 evaluable patients randomized to a single intratympanic injection of OTO-313 or placebo (1:1 randomization) and then followed for eight weeks. Patients reported the severity of their tinnitus symptoms using the Tinnitus Functional Index (TFI), a clinically-validated instrument, and by the daily reporting of their tinnitus loudness and annoyance. The trial achieved its objectives by demonstrating a positive clinical signal for OTO-313 based on a TFI responder analysis, with a favorable safety profile. Given these results, Otonomy intends to advance OTO-313 into full Phase 2 development which may include evaluation of a higher dose and/or retreatment with OTO-313.

Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus

Management will review the OTIVIDEX statistical analysis plan update together with the positive top-line OTO-313 Phase 1/2 trial results during a conference call today at 4:30 p.m. ET Management will review the OTIVIDEX statistical analysis plan update together with the positive top-line OTO-313 Phase 1/2 trial results during a conference call today at 4:30 p.m. ET

Otonomy Provides Update on OTIVIDEX® Program

Conference call and webcast today at 4:30 p.m. ET

Otonomy Provides Update on Clinical Trials and Development Programs

Otonomy (OTIC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Otonomy (OTIC) in Focus: Stock Moves 6.1% Higher

SAN DIEGO, June  11, 2020  (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present a company overview at the Raymond James 2020 Human Health Innovation Conference (Virtual) on Thursday June 18, 2020 at 2:20 p.m. ET (11:20 a.m. PT).

Otonomy to Present at Raymond James 2020 Human Health Innovation Conference

SAN DIEGO, June  10, 2020  (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that due to the health, safety and travel concerns of stockholders and federal, state and local government recommendations and restrictions imposed in response to the novel coronavirus (COVID-19) pandemic, the location of its 2020 Annual Meeting of Stockholders has changed. The Annual Meeting of Stockholders will be held virtually, by webcast, and stockholders will not be able to attend in person. The meeting will be held on the same date and time as originally scheduled, Tuesday, June 23, 2020 at 8 a.m. PDT. 

Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020

Conference call to review status of clinical trials and timing to results to be held in June Conference call to review status of clinical trials and timing to results to be held in June

Otonomy Reports First Quarter 2020 Financial Results and  Provides Corporate Update

SAN DIEGO, April  09, 2020  (GLOBE NEWSWIRE) --  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a business update related to the COVID-19 pandemic.

Otonomy Provides Business Update Related to COVID-19 Pandemic

Otonomy's (OTIC) CEO David Weber on Q4 2019 Results - Earnings Call Transcript

Otonomy (OTIC) delivered earnings and revenue surprises of 23.40% and -15.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Otonomy (OTIC) Reports Q4 Loss, Misses Revenue Estimates

Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.

Do Options Traders Know Something About Otonomy (OTIC) Stock We Don't?

SAN DIEGO, Jan.  28, 2020  (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the company’s gene therapy collaboration with Applied Genetic Technologies Corporation (Nasdaq: AGTC) focused initially on treating GJB2 deficiency for congenital hearing loss, and preclinical results demonstrating the therapeutic potential of a class of compounds being evaluated for otoprotection against cisplatin-induced hearing loss (CIHL). These results were presented during the ongoing Association for Research in Otolaryngology (ARO) 43rd Annual MidWinter Meeting being held in San Jose, California.

Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program

Three programs with clinical trial results in 2020 including OTIVIDEX™    Phase 3 trial in Ménière’s disease

Otonomy Provides Corporate and Product Pipeline Update

As of late, it has definitely been a great time to be an investor in Otonomy.

Will Otonomy Continue to Surge Higher?

Otonomy's (OTIC) CEO David Weber on Q3 2019 Results - Earnings Call Transcript

Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Otonomy (OTIC) to Report a Decline in Earnings: What to Look Out for

Applied Genetic Technologies

Initial focus on GJB2, the most common cause of genetic hearing loss in newborns Initial focus on GJB2, the most common cause of genetic hearing loss in newborns

AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

SAN DIEGO, Sept.  26, 2019  (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 12:35 p.m. ET (9:35 a.m. PT) at the InterContinental New York Barclay Hotel in New York City.

Otonomy to Present at the Cantor Global Healthcare Conference

Results expected in second half of 2020 Results expected in second half of 2020

Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss

Otonomy's (OTIC) CEO David Weber on Q2 2019 Results - Earnings Call Transcript

News for Otonomy Stock (OTIC)